Novel FR-900493 Analogues That Inhibit the Outgrowth of Spores

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2018 Mar 6

PMID 29503973

Citations 15

Authors

Katsuhiko Mitachi

Hyun Gi Yun

Sara M Kurosu

Shakiba Eslamimehr

Maddie R Lemieux

Lada Klaic

William M Clemons Jr

Michio Kurosu

Affiliations

Soon will be listed here.

Abstract

The spectrum of antibacterial activity for the nucleoside antibiotic FR-900493 () can be extended by chemical modifications. We have generated a small focused library based on the structure of and identified UT-17415 (), UT-17455 (), UT-17460 (), and UT-17465 (), which exhibit anti- growth inhibitory activity. These analogues also inhibit the outgrowth of spores at 2× minimum inhibitory concentration. One of these analogues, , relative to exhibits over 180-fold and 15-fold greater activity against the enzymes, phospho-MurNAc-pentapeptide translocase (MraY) and polyprenyl phosphate-GlcNAc-1-phosphate transferase (WecA), respectively. The phosphotransferase inhibitor displays antimicrobial activity against several tested bacteria including , , and , but no growth inhibitory activity is observed against the other Gram-positive and Gram-negative bacteria. The selectivity index (Vero cell cytotoxicity/antimicrobial activity) of is approximately 17, and does not induce hemolysis even at a 100 μM concentration.

Citing Articles

Potent and specific antibiotic combination therapy against Clostridioides difficile.

Chioti V, McWhorter K, Blue T, Li Y, Xu F, Jeffrey P Nat Chem Biol. 2024; 20(7):924-933.

PMID: 38942968 PMC: 11306116. DOI: 10.1038/s41589-024-01651-z.

Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement.

Lalhmangaihzuala S, Vanlaldinpuia K, Khiangte V, Laldinpuii Z, Liana T, Lalhriatpuia C Mol Divers. 2024; 28(6):4553-4579.

PMID: 38554170 DOI: 10.1007/s11030-024-10810-2.

Concise Synthesis of Tunicamycin V and Discovery of a Cytostatic DPAGT1 Inhibitor.

Mitachi K, Mingle D, Effah W, Sanchez-Ruiz A, Hevener K, Narayanan R Angew Chem Int Ed Engl. 2022; 61(31):e202203225.

PMID: 35594368 PMC: 9329268. DOI: 10.1002/anie.202203225.

A Convenient Protecting Group for Uridine Ureido Nitrogen: (4,4'-Bisfluorophenyl)methoxymethyl group.

Mitachi K, Mingle D, Kurosu M Synthesis (Stuttg). 2022; 53(15):2643-2650.

PMID: 35431351 PMC: 9009825. DOI: 10.1055/a-1464-2473.

Antibacterial Activity of Pharmaceutical-Grade Rose Bengal: An Application of a Synthetic Dye in Antibacterial Therapies.

Kurosu M, Mitachi K, Yang J, Pershing E, Horowitz B, Wachter E Molecules. 2022; 27(1).

PMID: 35011554 PMC: 8746496. DOI: 10.3390/molecules27010322.

References

Tanino T, Al-Dabbagh B, Mengin-Lecreulx D, Bouhss A, Oyama H, Ichikawa S . Mechanistic analysis of muraymycin analogues: a guide to the design of MraY inhibitors. J Med Chem. 2011; 54(24):8421-39. DOI: 10.1021/jm200906r. View

Stoltz K, Erickson R, Staley C, Weingarden A, Romens E, Steer C . Synthesis and Biological Evaluation of Bile Acid Analogues Inhibitory to Clostridium difficile Spore Germination. J Med Chem. 2017; 60(8):3451-3471. PMC: 5877410. DOI: 10.1021/acs.jmedchem.7b00295. View

Siricilla S, Mitachi K, Wan B, Franzblau S, Kurosu M . Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors. J Antibiot (Tokyo). 2014; 68(4):271-8. PMC: 4382465. DOI: 10.1038/ja.2014.133. View

Siricilla S, Mitachi K, Skorupinska-Tudek K, Swiezewska E, Kurosu M . Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I. Anal Biochem. 2014; 461:36-45. PMC: 4296562. DOI: 10.1016/j.ab.2014.05.018. View

Wang Y, Kurosu M . A new protecting group and linker for uridine ureido nitrogen. Tetrahedron. 2012; 68(24):4797-4804. PMC: 3375706. DOI: 10.1016/j.tet.2012.03.121. View

Kent W . BLAT--the BLAST-like alignment tool. Genome Res. 2002; 12(4):656-64. PMC: 187518. DOI: 10.1101/gr.229202. View

Wang Y, Siricilla S, Aleiwi B, Kurosu M . Improved synthesis of capuramycin and its analogues. Chemistry. 2013; 19(41):13847-58. PMC: 3929971. DOI: 10.1002/chem.201302389. View

Aleiwi B, Schneider C, Kurosu M . Synthesis of ureidomuraymycidine derivatives for structure-activity relationship studies of muraymycins. J Org Chem. 2012; 77(8):3859-67. PMC: 3374721. DOI: 10.1021/jo300205b. View

Al-Dabbagh B, Mengin-Lecreulx D, Bouhss A . Purification and characterization of the bacterial UDP-GlcNAc:undecaprenyl-phosphate GlcNAc-1-phosphate transferase WecA. J Bacteriol. 2008; 190(21):7141-6. PMC: 2580700. DOI: 10.1128/JB.00676-08. View

10.

van Beurden Y, Nieuwdorp M, van de Berg P, Mulder C, Goorhuis A . Current challenges in the treatment of severe infection: early treatment potential of fecal microbiota transplantation. Therap Adv Gastroenterol. 2017; 10(4):373-381. PMC: 5405882. DOI: 10.1177/1756283X17690480. View

11.

Mitachi K, Siricilla S, Yang D, Kong Y, Skorupinska-Tudek K, Swiezewska E . Fluorescence-based assay for polyprenyl phosphate-GlcNAc-1-phosphate transferase (WecA) and identification of novel antimycobacterial WecA inhibitors. Anal Biochem. 2016; 512:78-90. PMC: 5012913. DOI: 10.1016/j.ab.2016.08.008. View

12.

Howerton A, Patra M, Abel-Santos E . Fate of ingested Clostridium difficile spores in mice. PLoS One. 2013; 8(8):e72620. PMC: 3758320. DOI: 10.1371/journal.pone.0072620. View

13.

Tsutsumi L, Owusu Y, Hurdle J, Sun D . Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem. 2013; 14(1):152-75. PMC: 3921470. DOI: 10.2174/1568026613666131113154753. View

14.

Kurosu M, Li K, Crick D . Concise synthesis of capuramycin. Org Lett. 2009; 11(11):2393-6. PMC: 4784474. DOI: 10.1021/ol900458w. View

15.

Mitachi K, Aleiwi B, Schneider C, Siricilla S, Kurosu M . Stereocontrolled Total Synthesis of Muraymycin D1 Having a Dual Mode of Action against Mycobacterium tuberculosis. J Am Chem Soc. 2016; 138(39):12975-12980. PMC: 5053896. DOI: 10.1021/jacs.6b07395. View

16.

Allen C, Babakhani F, Sears P, Nguyen L, Sorg J . Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrob Agents Chemother. 2012; 57(1):664-7. PMC: 3535933. DOI: 10.1128/AAC.01611-12. View

17.

Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein A . Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis. 2012; 55 Suppl 2:S162-9. PMC: 3388029. DOI: 10.1093/cid/cis453. View

18.

Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H . OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006; 3(11):e466. PMC: 1664607. DOI: 10.1371/journal.pmed.0030466. View

19.

Winn M, Goss R, Kimura K, Bugg T . Antimicrobial nucleoside antibiotics targeting cell wall assembly: recent advances in structure-function studies and nucleoside biosynthesis. Nat Prod Rep. 2010; 27(2):279-304. DOI: 10.1039/b816215h. View

20.

Kimura K, Bugg T . Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis. Nat Prod Rep. 2003; 20(2):252-73. DOI: 10.1039/b202149h. View